| DNA methylation signatures identify biologically distinct thyroid cancer subtypes S Rodríguez-Rodero, AF Fernández, JL Fernández-Morera, ... The Journal of Clinical Endocrinology & Metabolism 98 (7), 2811-2821, 2013 | 149 | 2013 |
| Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness S Muñoz-Galván, B Felipe-Abrio, EM Verdugo-Sivianes, M Perez, ... Molecular cancer 19, 1-16, 2020 | 82 | 2020 |
| Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA M Perez, S Munoz-Galvan, MP Jimenez-Garcia, JJ Marin, A Carnero Oncotarget 6 (38), 40557, 2015 | 66 | 2015 |
| The cargo protein MAP17 (PDZK1IP1) regulates the cancer stem cell pool activating the Notch pathway by abducting NUMB JM Garcia-Heredia, A Lucena-Cacace, EM Verdugo-Sivianes, M Pérez, ... Clinical Cancer Research 23 (14), 3871-3883, 2017 | 63 | 2017 |
| MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival M Perez, JM Praena-Fernandez, B Felipe-Abrio, MA Lopez-Garcia, ... PLoS One 8 (2), e56169, 2013 | 50 | 2013 |
| The Clinical Significance of Unknown Sequence Variants in BRCA Genes V Calò, L Bruno, LL Paglia, M Perez, N Margarese, FD Gaudio, A Russo Cancers 2 (3), 1644-1660, 2010 | 44 | 2010 |
| Tumor cell-secreted PLD increases tumor stemness by senescence-mediated communication with microenvironment S Muñoz-Galván, A Lucena-Cacace, M Perez, D Otero-Albiol, ... Oncogene 38 (8), 1309-1323, 2019 | 42 | 2019 |
| Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src M Perez, A Lucena-Cacace, LM Marín-Gómez, J Padillo-Ruiz, ... Oncotarget 7 (22), 33111, 2016 | 42 | 2016 |
| Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors I Ferrer, EM Verdugo-Sivianes, MA Castilla, R Melendez, JJ Marin, ... Oncogene 35 (21), 2777-2788, 2016 | 37 | 2016 |
| Conditional transgenic expression of PIM1 kinase in prostate induces inflammation-dependent neoplasia M Narlik-Grassow, C Blanco-Aparicio, Y Cecilia, M Perez, ... PloS one 8 (4), e60277, 2013 | 36 | 2013 |
| MAP17 (PDZKIP1) expression determines sensitivity to the proteasomal inhibitor bortezomib by preventing cytoprotective autophagy and NFκB activation in breast cancer S Muñoz-Galván, G Gutierrez, M Perez, A Carnero Molecular cancer therapeutics 14 (6), 1454-1465, 2015 | 33 | 2015 |
| Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1) M Perez, J Peinado-Serrano, JM Garcia-Heredia, I Felipe-Abrio, C Tous, ... Oncotarget 7 (41), 67033, 2016 | 24 | 2016 |
| MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma I Ferrer, Á Quintanal-Villalonga, S Molina-Pinelo, JM Garcia-Heredia, ... Journal of Experimental & Clinical Cancer Research 37, 1-13, 2018 | 22 | 2018 |
| Breast tumor cells promotes the horizontal propagation of EMT, stemness, and metastasis by transferring the MAP17 protein between subsets of neoplastic cells JM García-Heredia, D Otero-Albiol, M Pérez, E Pérez-Castejón, ... Oncogenesis 9 (10), 96, 2020 | 14 | 2020 |
| Sarcoma stratification by combined pH2AX and MAP17 (PDZK1IP1) levels for a better outcome on doxorubicin plus olaparib treatment M Perez, JM García-Heredia, B Felipe-Abrio, S Muñoz-Galván, ... Signal Transduction and Targeted Therapy 5 (1), 195, 2020 | 13 | 2020 |
| The single nucleotide variant rs2868371 associates with the risk of mortality in non-small cell lung cancer patients: a multicenter prospective validation M del Valle Enguix-Riego, J Cacicedo, BDD León, JMNG Gómez, ... Radiotherapy and Oncology 136, 29-36, 2019 | 8 | 2019 |
| Patient-derived xenografts as models for personalized medicine research in cancer M Perez, L Navas, A Carnero Cancer Translational Medicine 2 (6), 2016 | 6 | 2016 |
| Phase II trial of palbociclib in advanced sarcoma overexpressing CDK4 gene excluding dedifferentiated liposarcoma (DD LPS): A study from the Spanish Group for … J Martin Broto, J Martinez Garcia, DS Moura, A Redondo, A Gutierrez, ... Journal of Clinical Oncology 40 (16_suppl), 11511-11511, 2022 | 4 | 2022 |
| Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A J Martin-Broto, J Martinez-Garcia, DS Moura, A Redondo, A Gutierrez, ... Signal transduction and targeted therapy 8 (1), 405, 2023 | 3 | 2023 |
| Pim1 kinase cooperates with hormone treatment to promote bladder and ureteral urothelial hyperplasia M Narlik-Grassow, C Blanco-Aparicio, Y Cecilia, M Pérez, ... OMICS Publishing Group, 2014 | 3 | 2014 |
